Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction - VICTORIA

Aug 30, 2025
Font Size
A
A
A
Author/Summarized by Author:
Anthony A. Bavry, MD,MPH,FACC
Summary Reviewer:
Fred M. Kusumoto, MD, FACC; Deepak L. Bhatt, MD, MPH, MBA, FACC; Kim A. Eagle, MD, MACC
Date Updated:
08/30/2025
Original Posted Date:
03/28/2020
References

Highlighted text has been updated as of Aug. 30, 2025.

Contribution To Literature:

The VICTORIA trial showed that vericiguat was superior to placebo at improving heart failure outcomes. A pooled analysis of VICTORIA and VICTOR trials demonstrated that vericiguat may provide a valuable option for selected patients with HFrEF.

Description:

The goal of the trial was to evaluate vericiguat compared with placebo among patients with chronic heart failure (CHF) due to reduced ejection fraction (EF). Vericiguat increases soluble guanylate cyclase activity. By stimulating production of cyclic guanosine monophosphate, this may help to improve myocardial and vascular function.

Study Design

  • Randomized
  • Double-blind
  • Parallel

Patients with CHF were randomized to vericiguat (n = 2,526) versus placebo (n = 2,524). Vericiguat started at 2.5 mg daily, increased to 5 mg daily, then 10 mg daily.

  • Total number of enrollees: 5,050
  • Duration of follow-up: 12 months
  • Mean patient age: 68 years
  • Percentage female: 24%

Inclusion criteria:

  • CHF; New York Heart Association class II-IV, left ventricular EF <45%, and guideline-directed heart failure therapy
  • Recent heart failure hospitalization or intravenous diuretic use
  • Elevated natriuretic peptides; N-terminal pro–B-type natriuretic peptide (NT-proBNP) ≥1000 pg/ml (≥1600 pg/ml if atrial fibrillation) or BNP ≥300 pg/ml (≥500 pg/ml if atrial fibrillation)
  • Clinically stable (systolic blood pressure ≥100 mm Hg and no intravenous diuretics for 24 hours)

Exclusion criteria:

  • Use of long-acting nitrates, phosphodiesterase type 5 inhibitor, riociguat
  • Awaiting heart transplantation, continuous intravenous diuretics, or current/anticipated ventricular assist device
  • Chronic kidney disease (estimated glomerular filtration rate 15 ml/min/1.73 m2) or dialysis
  • Severe pulmonary disease requiring continuous oxygen
  • Severe hepatic insufficiency
  • Correctable cardiac comorbidities

Other salient features/characteristics:

  • Mean EF: 29%
  • Target dose of vericiguat achieved in 89%

Principal Findings:

The primary outcome, cardiovascular death or hospitalization for heart failure, occurred in 35.5% of the vericiguat group compared with 38.5% of the placebo group (hazard ratio [HR] 0.90, p = 0.019). The risk of the primary outcome for vericiguat vs. placebo was not modified by age (p for interaction = 0.17) or sex (p for interaction = 0.85).

Secondary outcomes:

  • Cardiovascular death: 16.4% of the vericiguat group compared with 17.5% of the placebo group (p = 0.27)
  • All-cause death: 20.3% of the vericiguat group compared with 21.2% of the placebo group (p = 0.38)
  • Heart failure hospitalization: 27.4% of the vericiguat group compared with 29.6% of the placebo group (p = 0.048)
  • Serious adverse event: 32.8% of the vericiguat group compared with 34.8% of the placebo group

Recurrent heart failure hospitalizations:

  • Total heart failure hospitalizations and cardiovascular death: 3.6% with vericiguat vs. 3.9% with placebo (95% confidence interval [CI] 0.84-1.01)
  • No significant difference in treatment effect between patients with vs. without heart failure hospitalization

Hemoglobin and clinical outcomes:

  • Occurrence of new anemia: 13.6% with vericiguat compared with 10.5% with placebo (p < 0.001)
  • Among those with hemoglobin ≤15 g/dl, there was increasing risk for the primary outcome with a lower hemoglobin (HR 1.15 per 1 g/dl hemoglobin decrease)
  • However, the relationship between vericiguat compared with placebo and the primary outcome was preserved, when hemoglobin was added as a time-dependent variable (hemoglobin <15 g/dl, p for interaction = 0.104)

Quality-adjusted life expectancy:

  • Vericiguat increased quality-adjusted life expectancy by 0.43 years vs. placebo (estimated cost $66,509 per quality-adjusted life-year with interaction term).
  • Vericiguat increased quality-adjusted life expectancy by 0.17 years vs. placebo (estimated cost $124,512 per quality-adjusted life-year without interaction term).

Diabetes status and clinical outcomes (p for interaction = 0.75):

  • History of diabetes: HR 0.92 (95% CI 0.81-1.04)
  • Diabetes measured by glycosylated hemoglobin: HR 0.77 (95% CI 0.49-1.20)
  • Pre-diabetes: HR 0.88 (95% CI 0.68-1.13)
  • Normoglycemia: HR 1.02 (95% CI 0.75-1.39)

Prespecified pooled analysis of VICTORIA (n=5,050) and VICTOR (n=6,105):

  • Primary composite endpoint of cardiovascular death or first hospitalization for heart failure: 25.9% for vericiguat vs. 27.9% for placebo (HR 0.91, 95% CI 0.85-0.98; p=0.0088)
  • Cardiovascular death (HR 0.89, 95% CI 0.80-0.98; p=0.020)
  • All-cause death (HR 0.90, 95% CI 0.82-0.99; p=0.025)
  • First hospitalization for heart failure alone (HR 0.92; 95% CI 0.84-1.00; p=0.043)

Interpretation:

Among patients with CHF with recent decompensation, a novel strategy of increasing soluble guanylate cyclase activity with vericiguat was effective. Vericiguat compared with placebo was effective at reducing cardiovascular death or hospitalization for heart failure. There was no treatment interaction according to age, sex, or diabetes. There was no apparent reduction in all-cause mortality with vericiguat compared with placebo. Vericiguat was safe and well tolerated and did not require monitoring of renal function or electrolytes. From a cost-effectiveness standpoint, vericiguat is considered of intermediate value. Vericiguat may represent a novel treatment among patients with recent heart failure decompensation. Vericiguat was associated with new anemia; however, the benefit of vericiguat compared with placebo on prevention of adverse events was preserved when hemoglobin was considered in a time-updated model.

The pooled analysis of the VICTORIA and VICTOR trials showed that vericiguat led to a moderate but significant reduction in the primary composite endpoint of cardiovascular death or first heart failure hospitalization and in cardiovascular and all-cause death, with a borderline effect on first heart failure hospitalization in this patient population. The benefits were more apparent in patients with baseline NT-proBNP ≤6000 pg/mL. Thus, a once-daily dose of vericiguat should be considered a treatment option for appropriately selected patients (e.g., those unable to tolerate high doses of quadruple drugs due to low blood pressure or renal limitations).

References:

Zannad F, O'Connor CM, Butler J, et al., for the VICTORIA and VICTOR Study Groups. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet 2025;Aug 30:[Epub ahead of print].

Editorial Comment: Kohsaka S, Heidenreich PA. Vericiguat across the heart failure spectrum. Lancet 2025;Aug 30:[Epub ahead of print].

Presented by Dr. Faiez Zannad at the European Society of Cardiology Congress, Madrid, Spain, Aug. 30, 2025.

Khan MS, Butler J, Young R, et al., on behalf of the VICTORIA Study Group. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial. JACC Heart Fail 2024;12:1750-9.

Editorial Comment: Scirica BM. Vericiguat, Diabetes, and Heart Failure: How Can You Tell If There Is “There” There? JACC Heart Fail 2024;12:1760-1.

Mentz RJ, Stebbins A, Butler J, et al., on behalf of the VICTORIA Study Group. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction. JACC Heart Fail 2024;12:839-46.

Chew DS, Li Y, Bigelow R, et al., on behalf of the VICTORIA Study Group. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial. Circulation 2023;148:1087-98.

Lam CS, Piña IL, Zheng Y, et al., on behalf of the VICTORIA Study Group. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial. JACC Heart Fail 2023;11:1246-57.

Editorial Comment: Hsich EM. “We Are the Champions”: Victory for VICTORIA Trial. JACC Heart Fail 2023;11:1258-61.

Ezekowitz JA, Zheng Y, Cohen-Solal A, et al., on behalf of the VICTORIA Study Group. Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation 2021;144:1489-99.

Armstrong PW, Pieske B, Anstrom KJ, et al., on behalf of the VICTORIA Study Group. Vericiguat in Patients With Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020;382:1883-93.

Editorial: Burnett JC Jr. Vericiguat — Another Victory for Targeting Cyclic GMP in Heart Failure. N Engl J Med 2020;382:1952-3.

Presented by Dr. Paul W. Armstrong at the American College of Cardiology Virtual Annual Scientific Session Together With World Congress of Cardiology (ACC 2020/WCC), March 28, 2020.

Clinical Topics: Heart Failure and Cardiac Biomarkers

Keywords: ESC25, ESC Congress, ACC International


< Back to Listings